In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

Shaunna L. Beedie, Holly M. Rore, Shelby Barnett, Cindy H. Chau, Weiming Luo, Nigel H. Greig, William D. Figg, Neil Vargesson

Research output: Contribution to journalArticle

16 Citations (Scopus)
3 Downloads (Pure)

Abstract

Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.
Original languageEnglish
Pages (from-to)33237-33245
Number of pages9
JournalOncotarget
Volume7
Issue number22
DOIs
Publication statusPublished - 22 Apr 2016

Fingerprint

Thalidomide
Zebrafish
Chickens
Embryonic Structures
Leprosy
Multiple Myeloma
Anti-Inflammatory Agents
Pharmaceutical Preparations
Therapeutics

Keywords

  • angiogenesis
  • inflammation
  • thalidomide
  • cancer
  • teratogenesis

Cite this

In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. / Beedie, Shaunna L.; Rore, Holly M.; Barnett, Shelby; Chau, Cindy H. ; Luo, Weiming ; Greig, Nigel H.; Figg, William D.; Vargesson, Neil.

In: Oncotarget, Vol. 7, No. 22, 22.04.2016, p. 33237-33245.

Research output: Contribution to journalArticle

Beedie, Shaunna L. ; Rore, Holly M. ; Barnett, Shelby ; Chau, Cindy H. ; Luo, Weiming ; Greig, Nigel H. ; Figg, William D. ; Vargesson, Neil. / In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 33237-33245.
@article{e3fe86ac67bf4f1b8a39aacf3508b4c0,
title = "In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems",
abstract = "Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.",
keywords = "angiogenesis, inflammation, thalidomide, cancer , teratogenesis",
author = "Beedie, {Shaunna L.} and Rore, {Holly M.} and Shelby Barnett and Chau, {Cindy H.} and Weiming Luo and Greig, {Nigel H.} and Figg, {William D.} and Neil Vargesson",
note = "This study was supported by a Wellcome Trust-NIH PhD Studentship to SB, WDF and NV. Grant number 098252/Z/12/Z. SB, CHC and WDF are supported by the Intramural Research Program, NCI, NIH. NHG and WL are supported by the Intramural Research Program, NIA, NIH.",
year = "2016",
month = "4",
day = "22",
doi = "10.18632/oncotarget.8909",
language = "English",
volume = "7",
pages = "33237--33245",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "22",

}

TY - JOUR

T1 - In Vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems

AU - Beedie, Shaunna L.

AU - Rore, Holly M.

AU - Barnett, Shelby

AU - Chau, Cindy H.

AU - Luo, Weiming

AU - Greig, Nigel H.

AU - Figg, William D.

AU - Vargesson, Neil

N1 - This study was supported by a Wellcome Trust-NIH PhD Studentship to SB, WDF and NV. Grant number 098252/Z/12/Z. SB, CHC and WDF are supported by the Intramural Research Program, NCI, NIH. NHG and WL are supported by the Intramural Research Program, NIA, NIH.

PY - 2016/4/22

Y1 - 2016/4/22

N2 - Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

AB - Thalidomide, a drug known for its teratogenic side-effects, is used successfully to treat a variety of clinical conditions including leprosy and multiple myeloma. Intense efforts are underway to synthesize and identify safer, clinically relevant analogs. Here, we conduct a preliminary in vivo screen of a library of new thalidomide analogs to determine which agents demonstrate activity, and describe a cohort of compounds with anti-angiogenic properties, anti-inflammatory properties and some compounds which exhibited both. The combination of the in vivo zebrafish and chicken embryo model systems allows for the accelerated discovery of new, potential therapies for cancerous and inflammatory conditions.

KW - angiogenesis

KW - inflammation

KW - thalidomide

KW - cancer

KW - teratogenesis

U2 - 10.18632/oncotarget.8909

DO - 10.18632/oncotarget.8909

M3 - Article

VL - 7

SP - 33237

EP - 33245

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -